Cencora (COR)

• Market cap: $55.5B
• 1 day: 0.88%
• 5 days: -2.50%
• 1 month: 4.52%
• 3 months: 16.19%
• 6 months: 14.93%
• Year to date: 27.38%
• 1 year: 27.75%
• 5 years: 215.84%
• 10 years: 149.13%
• Sector: Healthcare
• Industry: Medical Distribution

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

91% more first-time investments, than exits

New positions opened: 172 | Existing positions closed: 90

30% more call options, than puts

Call options by funds: $1.2B | Put options by funds: $924M

23% more repeat investments, than reductions

Existing positions increased: 473 | Existing positions reduced: 385

5% more funds holding

Funds holding: 1,145 [Q3] → 1,203 (+58) [Q4]

1.54% more ownership

Funds ownership: 98.55% [Q3] → 100.09% (+1.54%) [Q4]

0% less capital invested

Capital invested by funds: $43.7B [Q3] → $43.5B (-$214M) [Q4]

20% less funds holding in top 10

Funds holding in top 10: 15 [Q3] → 12 (-3) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $274 4% downside
• Avg. target: $320 12% upside
• High target: $355 24% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Citigroup Michael Rollins 71% 1-year accuracy 20 / 28 met price target	24% upside $355	Buy Maintained	8 May 2025
Baird David Rodgers 32% 1-year accuracy 10 / 31 met price target	22% upside $350	Outperform Maintained	8 May 2025
UBS Kevin Caliendo 65% 1-year accuracy 11 / 17 met price target	17% upside $335	Buy Maintained	29 Apr 2025
B of A Securities Michael Funk 50% 1-year accuracy 3 / 6 met price target	0% downside $285	Neutral Maintained	11 Apr 2025
Wells Fargo Stephen Baxter 30% 1-year accuracy 9 / 30 met price target	4% downside $274	Equal-Weight Maintained	14 Mar 2025